Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adam, R.
Right arrow Articles by Bismuth, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adam, R.
Right arrow Articles by Bismuth, F.
Related Collections
Right arrow Chemotherapy
Right arrow Surgery
Annals of Surgical Oncology 8:347-353 (2001)
© 2001 Society of Surgical Oncology

ORIGINAL ARTICLES

Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases

R. Adam, MD, PhD, E. Avisar, MD, A. Ariche, MD, S. Giachetti, MD, D. Azoulay, MD, PhD, D. Castaing, MD, F. Kunstlinger, MD, F. Levi, MD and F. Bismuth, MD

From the Centre Hépato-Biliaire (RA, EA, AA, DA, DC, FK, HB), and Centre de Chronothérapie (SG, FL), Service de Cancérologie Hopital Paul Brousse, Villejuif, France.

Correspondence: Address correspondence and reprint requests to: Pr. Rene Adam, Centre Hepato-Biliaire, Hopital Paul Brousse, 12, Av. Paul Vaillant Couturier, BP 200 - 94804 VILLEJUIF Cedex, France; Fax: 01-45-59-38-57; E-mail: rene.adam{at}pbr.ap-hop-paris.fr

Background: Surgical resection is the most effective treatment for colorectal liver metastases but only a minority of patients are candidates for a potentially curative resection. Our experience with neoadjuvant chemotherapy followed by resection and five years survival analysis of the patients treated is presented.

Methods: Between February of 1988 and September of 1996, 701 patients with unresectable colorectal liver metastases were treated with neoadjuvant chemotherapy. Four categories of nonresectable disease were defined: large size, ill location, multinodularity, and extrahepatic disease. Liver resection was performed in those patients whose disease became resectable. After resection, the patients were followed up every 3 months. A 5-year survival analysis by the different categories described was performed.

Results: Ninety-five patients (13.5%) were found to be resectable on reevaluation and underwent a potentially curative resection. There was no perioperative mortality, and the complication rate was 23%. As of December of 1999, 87 patients have completed 5 years of follow-up. The overall 5-year survival is 35% from the time of resection and 39% from the onset of chemotherapy. Respective 5-year survival rates are 60% for large tumors, 49% for ill-located lesions, 34% for multinodular disease, and 18% for liver metastases with extrahepatic disease. In this latter category, however, a 35% 5-year survival was found when all the patients with extrahepatic disease were analyzed rather than only those for whom extrahepatic disease was the main cause of nonresectability.

Conclusions: Neoadjuvant chemotherapy enables liver resection in some patients with initially unresectable colorectal metastases. Long-term survival is similar to that reported for a priori surgical candidates.

Key Words: Neoadjuvant therapy • Chronotherapy • Colorectal liver metastases • Nonresectable hepatic metastases




This article has been cited by other articles:


Home page
 JCOHome page
B. C. Pestalozzi, S. Gruttadauria, and P.-A. Clavien
Hepatic Arterial Infusion: The Beginning of the Combination Era
J. Clin. Oncol., May 1, 2008; 26(13): 2231 - 2232.
[Full Text] [PDF]

Home page
 JCOHome page
R. Adam, D. A. Wicherts, R. J. de Haas, T. Aloia, F. Levi, B. Paule, C. Guettier, F. Kunstlinger, V. Delvart, D. Azoulay, et al.
Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?
J. Clin. Oncol., April 1, 2008; 26(10): 1635 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. M. Pawlik, R. D. Schulick, and M. A. Choti
Expanding Criteria for Resectability of Colorectal Liver Metastases
Oncologist, January 1, 2008; 13(1): 51 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. Z. Malik, S. Farid, A. Al-Mukthar, A. Anthoney, G. J. Toogood, J. P. A. Lodge, and K. R. Prasad
A Critical Appraisal of the Role of Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Case-Controlled Study
Ann. Surg. Oncol., December 1, 2007; 14(12): 3519 - 3526.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. Elias, D. Goere, V. Boige, N. Kohneh-Sharhi, D. Malka, G. Tomasic, C. Dromain, and M. Ducreux
Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin
Ann. Surg. Oncol., November 1, 2007; 14(11): 3188 - 3194.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-N. Vauthey
Colorectal Liver Metastases: Treat Effectively Up Front and Consider the Borderline Resectable
J. Clin. Oncol., October 10, 2007; 25(29): 4524 - 4525.
[Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
P Sanghera, K Ho, T Muscroft, and A Hartley
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis
Br. J. Radiol., August 1, 2007; 80(956): e170 - e172.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. Niu, T. D. Yan, J. C. Zhu, D. Black, F. Chu, and D. L. Morris
Recurrence and Survival Outcomes after Hepatic Resection with or without Cryotherapy for Liver Metastases from Colorectal Carcinoma
Ann. Surg. Oncol., July 1, 2007; 14(7): 2078 - 2087.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al.
Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups
J. Clin. Oncol., June 1, 2007; 25(16): 2313 - 2321.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crino, G. Benedetti, W. Evangelista, L. Fanchini, et al.
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
J. Clin. Oncol., May 1, 2007; 25(13): 1670 - 1676.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. Tanaka, H. Shimada, M. Ueda, K. Matsuo, I. Endo, and S. Togo
Long-Term Characteristics of 5-Year Survivors After Liver Resection for Colorectal Metastases
Ann. Surg. Oncol., April 1, 2007; 14(4): 1336 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Ishiguro, T. Akasu, Y. Fujimoto, J. Yamamoto, Y. Sakamoto, T. Sano, K. Shimada, T. Kosuge, S. Yamamoto, S. Fujita, et al.
Second Hepatectomy for Recurrent Colorectal Liver Metastasis: Analysis of Preoperative Prognostic Factors
Ann. Surg. Oncol., December 1, 2006; 13(12): 1579 - 1587.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C. Charnsangavej, B. Clary, Y. Fong, A. Grothey, T. M. Pawlik, and M. A. Choti
Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
Ann. Surg. Oncol., October 1, 2006; 13(10): 1261 - 1268.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. K. Monga and M. J. O'Connell
Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions
Ann. Surg. Oncol., August 1, 2006; 13(8): 1021 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
O J Garden, M Rees, G J Poston, D Mirza, M Saunders, J Ledermann, J N Primrose, and R W Parks
Guidelines for resection of colorectal cancer liver metastases
Gut, August 1, 2006; 55(suppl_3): iii1 - iii8.
[Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem
Progress With Biological Agents in Metastatic Colorectal Cancer Leads to Many Challenges
J. Clin. Oncol., July 20, 2006; 24(21): 3325 - 3327.
[Full Text] [PDF]

Home page
 JCOHome page
G. Poston, R. Adam, and J.-N. Vauthey
Downstaging or Downsizing: Time for a New Staging System in Advanced Colorectal Cancer?
J. Clin. Oncol., June 20, 2006; 24(18): 2702 - 2706.
[Full Text] [PDF]

Home page
 Arch SurgHome page
T. M. Pawlik, J.-N. Vauthey, E. K. Abdalla, R. E. Pollock, L. M. Ellis, and S. A. Curley
Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver
Arch Surg, June 1, 2006; 141(6): 537 - 544.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
I K Beal, S Anthony, A Papadopoulou, R Hutchins, G Fusai, R Begent, N Davies, J Tibballs, and B Davidson
Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy.
Br. J. Radiol., June 1, 2006; 79(942): 473 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J.-N. Vauthey and E. K. Abdalla
Unresectable Hepatic Colorectal Metastases: Need for New Surgical Strategies
Ann. Surg. Oncol., January 1, 2006; 13(1): 5 - 6.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. Masi, S. Cupini, L. Marcucci, E. Cerri, F. Loupakis, G. Allegrini, I. M. Brunetti, E. Pfanner, M. Viti, O. Goletti, et al.
Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer
Ann. Surg. Oncol., January 1, 2006; 13(1): 58 - 65.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. R. Alberts, W. L. Horvath, W. C. Sternfeld, R. M. Goldberg, M. R. Mahoney, S. R. Dakhil, R. Levitt, K. Rowland, S. Nair, D. J. Sargent, et al.
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
J. Clin. Oncol., December 20, 2005; 23(36): 9243 - 9249.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Chong and D. Cunningham
Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066.
[Full Text] [PDF]

Home page
 JCOHome page
G. J. Poston, R. Adam, S. Alberts, S. Curley, J. Figueras, D. Haller, F. Kunstlinger, G. Mentha, B. Nordlinger, Y. Patt, et al.
OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer
J. Clin. Oncol., October 1, 2005; 23(28): 7125 - 7134.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. J. Petrelli, J. Abbruzzese, P. Mansfield, and B. Minsky
Hepatic Resection: The Last Surgical Frontier for Colorectal Cancer
J. Clin. Oncol., July 10, 2005; 23(20): 4475 - 4477.
[Full Text] [PDF]

Home page
 JCOHome page
H. Kelly and R. M. Goldberg
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
J. Clin. Oncol., July 10, 2005; 23(20): 4553 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. D. Leonard, B. Brenner, and N. E. Kemeny
Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal Carcinoma
J. Clin. Oncol., March 20, 2005; 23(9): 2038 - 2048.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. J. Poston
Radiofrequency Ablation of Colorectal Liver Metastases: Where Are We Really Going?
J. Clin. Oncol., March 1, 2005; 23(7): 1342 - 1344.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Delaunoit, S. R. Alberts, D. J. Sargent, E. Green, R. M. Goldberg, J. Krook, C. Fuchs, R. K. Ramanathan, S. K. Williamson, R. F. Morton, et al.
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741
Ann. Onc., March 1, 2005; 16(3): 425 - 429.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Sebagh, M. Plasse, F. Levi, and R. Adam
Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity?
Ann. Onc., February 1, 2005; 16(2): 331 - 331.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Masi, G. Allegrini, S. Cupini, L. Marcucci, E. Cerri, I. Brunetti, E. Fontana, S. Ricci, M. Andreuccetti, and A. Falcone
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
Ann. Onc., December 1, 2004; 15(12): 1766 - 1772.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
Z. Z. R. Hamady, A. Kotru, H. Nishio, and J. P. A. Lodge
Current techniques and results of liver resection for colorectal liver metastases
Br. Med. Bull., October 27, 2004; 70(1): 87 - 104.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Pozzo, M. Basso, A. Cassano, M. Quirino, G. Schinzari, N. Trigila, M. Vellone, F. Giuliante, G. Nuzzo, and C. Barone
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients
Ann. Onc., June 1, 2004; 15(6): 933 - 939.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Chau, M. J. Allen, D. Cunningham, A. R. Norman, G. Brown, H. E.R. Ford, N. Tebbutt, D. Tait, M. Hill, P. J. Ross, et al.
The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer
J. Clin. Oncol., April 15, 2004; 22(8): 1420 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. P. Venook
Testing the Water Before Diving Off the Cutting Edge
Ann. Surg. Oncol., May 1, 2003; 10(4): 332 - 333.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Ychou, T. Conroy, J. F. Seitz, S. Gourgou, A. Hua, D. Mery-Mignard, and A. Kramar
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
Ann. Onc., March 1, 2003; 14(3): 481 - 489.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Chemotherapy for metastatic colorectal cancer
DTB, July 1, 2002; 40(7): 49 - 52.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society of Surgical Oncology.